What records are connected here?
- Evidence lanes
- 3
- Source years
- 10
- Drugs@FDA applications
- 6
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Large human trialsCancer
Carfilzomib is a tetrapeptide epoxyketone, a modified chain of four amino acids, that blocks the proteasome, the cell’s protein-recycling machine. It is the active ingredient in Kyprolis.1,2 FDA approved Kyprolis in 2012. Its label covers relapsed or refractory multiple myeloma, alone or combined with other myeloma drugs.1,2 In the randomized ENDEAVOR trial of 929 people, median progression-free survival was 18.7 months with carfilzomib and dexamethasone versus 9.4 months with bortezomib and dexamethasone. The label has no boxed warning but warns of heart, kidney and lung toxicity.1
| What it is | A tetrapeptide epoxyketone proteasome inhibitor with the formula C40H57N5O7, according to the label.1 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists Kyprolis, NDA 202714, with an original approval date of July 20, 2012. The label has no boxed warning.1,2 |
| Human evidence | Several randomized, open-label phase 3 trials in relapsed or refractory multiple myeloma described in the label, including ASPIRE (792 people) and ENDEAVOR (929 people).1 |
| Evidence strength | Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned |
Carfilzomib is a tetrapeptide epoxyketone proteasome inhibitor, according to the label, which gives its molecular formula as C40H57N5O7.1
In the United States it is the active ingredient of Kyprolis, approved under NDA 202714, according to Drugs@FDA.2
The label states that it binds irreversibly to the active sites of the 20S proteasome, the core of the cell’s protein-degrading complex, and that it slowed growth and triggered death of tumour cells in laboratory studies.1
In ASPIRE, 792 people with relapsed or refractory multiple myeloma were randomized to carfilzomib with lenalidomide and dexamethasone or to lenalidomide and dexamethasone alone; median progression-free survival was 26.3 versus 17.6 months, and overall survival was also longer with carfilzomib, according to the label.1
In ENDEAVOR, 929 people were randomized to carfilzomib and dexamethasone or bortezomib and dexamethasone; median progression-free survival was 18.7 versus 9.4 months.1
Evidence-strength label: Large randomized human trials. How this label is assigned
Yes. Drugs@FDA lists Kyprolis, NDA 202714, with an original approval date of July 20, 2012.2
The Kyprolis label cited here (DailyMed SPL version 59, published June 26, 2025) states that it is indicated for adults with relapsed or refractory multiple myeloma who have had one to three lines of therapy, in combination with other myeloma drugs, and on its own after one or more lines of therapy.1
The label has no boxed warning. It warns of heart failure and other cardiac toxicities, acute kidney failure, tumour lysis syndrome, lung toxicity, pulmonary hypertension and shortness of breath, among other risks.1
Its use outside relapsed or refractory multiple myeloma, which its approved indication does not cover.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Carfilzomib: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Carfilzomib are a bounded selection, not every registration or paper about Carfilzomib. For the years before Carfilzomib was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Carfilzomib as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Carfilzomib in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Kyprolis for relapsed or refractory multiple myeloma. Approval rests on randomized trials including ASPIRE (792 people) and ENDEAVOR (929 people), which found longer progression-free survival. The label has no boxed warning.↗↗
Status sources checked through November 16, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Kyprolis for relapsed or refractory multiple myeloma. Approval rests on randomized trials including ASPIRE (792 people) and ENDEAVOR (929 people), which found longer progression-free survival. The label has no boxed warning.↗↗
The cited status sources were checked through November 16, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Clinical trials · source date November 16, 2026
ClinicalTrials.gov record NCT07715903↗Added to PeptideScanner November 17, 2026Clinical trials · added November 17, 2026
ClinicalTrials.gov record NCT07715903↗Source date November 16, 2026Clinical trials · added November 17, 2026
ClinicalTrials.gov record NCT03606577↗Source date November 12, 2026Clinical trials · added November 17, 2026
ClinicalTrials.gov record NCT06152575↗Source date November 12, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
29 of 29 selected trial records include at least one phase value; 29 of 29 include a status value in the retained structured contract.
25 of 25 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT03606577 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT06152575 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT07555938 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was carfilzomib.
25 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span April 27, 2012 to November 16, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07715903 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was carfilzomib.↗
Literature metadata
PubMed lists PMID 40397818 in Leukemia & lymphoma as Journal Article, Clinical Trial, Phase II, Multicenter Study, Clinical Trial, Phase I, with publication-date metadata of 2025-05-21 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03606577 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was carfilzomib.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06152575 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was carfilzomib.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07555938 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was carfilzomib.↗
Literature metadata
PubMed lists PMID 36529145 in The Lancet. Haematology as Clinical Trial, Phase II, Equivalence Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2022-12-15 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05497804 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was carfilzomib.↗
Literature metadata
PubMed lists PMID 35578151 in International journal of hematology as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2022-05-17 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 41134506 in International journal of hematology as Journal Article, Clinical Trial, Phase II, with publication-date metadata of 2025-10-24 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04430894 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-10-06, and PeptideScanner's reviewed identity mapping was carfilzomib.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04925193 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-10-02, and PeptideScanner's reviewed identity mapping was carfilzomib.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01559935 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was carfilzomib.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 16, 2026
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026